Cellartis DEF-CS 500 Culture System (Cat. No. Y30010)
500 ml Cellartis DEF-CS 500 Basal Medium (Cat. No. Y30011; not sold separay)
4 ml Cellartis DEF-CS 500 COAT-1 (Cat. No. Y30012)
Cellartis DEF-CS 500 Additives (Cat. No. Y30016):
o 2 x 750 µl DEF-CS GF-1
o 500 µl DEF-CS GF-2
o 200 µl DEF-CS GF-3
需要自行準備試劑:PBS(含鈣鎂和不含鈣鎂),TrypLE選擇酶(無酚紅)
PBS Dulbecco's with Ca2+ & Mg2+ (D-PBS +/+)
PBS Dulbecco's w/o Ca2+ & Mg2+ (D-PBS –/–)
TrypLE Select Enzyme (1X), no phenol red
誘導多能干細胞培養(yǎng)性能
單細胞傳代
Human induced pluripotent stem (iPS) cells can be passaged as single cells in the Cellartis DEF-CS Culture System. A single GFP-actin iPS cell was isolated and placed in the well of a culture dish. Twenty-four hours after seeding, morphology was assessed by fluorescence microscopy at 20x (Panel A) and 40x (Panel B) magnification. Sixteen days later, the single GFP-actin iPS cell had proliferated into numerous cells as evidenced by microscopic observation at 4x (Panel C), 10x (Panel D), 20x (Panel E), and 40x (Panel F) magnification.
擴增潛力
Expansion potential of a characterized working bank of human induced pluripotent stem (iPS) cells in the Cellartis DEF-CS Culture System. The Cellartis DEF-CS Culture System can produce 2 x 109 human iPS cells within 4 passages (18–20 days) from frozen cells (2.0–2.5 x 106 cells).
多能干性維持
Human pluripotent stem cells remain undifferentiated when cultured in the Cellartis DEF-CS Culture System. Human iPS cells cultured for 23 passages in the Cellartis DEF-CS Culture System were characterized by Oct-4 staining (A) and nuclear staining (B).
參考文獻:
1. Sivertsson, Louise, et al. "Hepatic differentiation and maturation of human embryonic stem cells cultured in a perfused three-dimensional bioreactor." Stem cells and development 22.4 (2012): 581-594.
2. Hanson, Charles, et al. "Transplantation of human embryonic stem cells onto a partially wounded human cornea in vitro." Acta ophthalmologica 91.2 (2013): 127-130.
3. Norrman, Karin, et al. "Distinct gene expression signatures in human embryonic stem cells differentiated towards definitive endoderm at single-cell level." Methods 59.1 (2013): 59-70.
4. Ulvestad, Maria, et al. "Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells." Biochemical pharmacology 86.5 (2013): 691-702.
5. Ramirez JM, et al. Side scatter intensity is highly heterogeneous in undifferentiated pluripotent stem cells and predicts clonogenic self-renewal. Stem Cells Dev.2013 Jun 15;22(12):1851-1860.
6. Borestrom, Cecilia, et al. “Footprint-free human induced pluripotent stem cells from articular cartilage with redifferentiation capacity: A first step toward a clinical-grade cell source.” Stem Cells Trans. Med. (2014) 3, 433-447.
7. Kia, Richard, et al. "MicroRNA-122: a novel hepatocyte-enriched in vitro marker of drug-induced cellular toxicity." Toxicological Sciences (2014): kfu269.
8. Valton, Julien, et al. "Efficient strategies for TALEN-mediated genome editing in mammalian cell lines." Methods 69.2 (2014): 151-170.
9. Zandén, Carl, et al. "Stem cell responses to plasma surface modified electrospun polyurethane scaffolds." Nanomedicine: Nanotechnology, Biology and Medicine 10.5 (2014): 949-958.
10. Asplund, Annika, et al. “One Standardized Differentiation Procedure Robustly Generates Homogenous Hepatocyte Cultures Displaying? Metabolic Diversity from a Large Panel of Human Pluripotent Stem Cells” Stem Cell Rev and Rep (2015)